Tuberculosis and other mycobacterial infections are the most serious infectious diseases in terms of human fatalities. The high content of unique cellwall lipids helps these organisms to resist antimicrobial drugs and host defences. The biosynthesis of these lipids is discussed briefly. The recent advances in recombinant DNA technology have begun to help to elucidate the nature of some of the enzymes involved in this process and the genes that encode them. Gene disruption and other molecular genetic technologies are beginning to provide new approaches to test for the biological functions of these gene products and may lead to identification of new antimycobacterial drug targets.
Introduction
Isolation of the tubercle bacillus (Mycobacterium tuberculosis) as the causative agent of tuberculosis in 1882, and Mycobacterium leprae as the causative agent of leprosy in 1873, created hopes that such discoveries would quickly lead to eradication of these diseases. During the first half of the 20th century, mycobacterial infection was one of the most intensively researched infectious diseases. With the introduction of streptomycin and isoniazid in the middle of this century, mycobacterial diseases began to decline in the industrialized world and interest in research into mycobacterial diseases dwindled. More recently, with the advent of aquired immune deficiency syndrome (AIDS), there has been a resurgence of mycobacterial infection in the industrialized nations. The World Health Organization (WHO) issued a gloomy tuberculosis (TB) report in 1996, indicating that more people died of TB in 1995 than in any other year in history (Najima, 1996) . According to this report, onethird of the world's population (equivalent to 2-billion people) is now infected and 5-10% of them will become sick; during the next decade 30-million people will die from TB. Although most of these fatalities will be in the developing world, with the spread of AIDS, TB infection is now appearing in parts of the world that were thought to be safe from TB. Reports that one person in Minneapolis infected 41 people in a neighbourhood bar, and a health care worker in western Canada gave TB to 100 people have helped to create public awareness of this problem. The most frightening aspect of mycobacterial diseases is the emergence of multidrug-resistant TB, especially in major cities of the world. WHO estimates that 50-million people are now infected with drug-resistant strains of the TB pathogen. In recent years the scientific community has become increasingly aware of this reemergent killer (Bloom and Murray, 1992; Hart et al., 1996) .
One of the major problems in combating mycobacterial diseases is that these bacteria produce unusual cell walls with low permeability, making them resistant to therapeutic agents. Successful antimycobacterial therapy includes the use of agents that inhibit the biosynthesis of cell-wall components. The widely used drug isoniazid inhibits the biosynthesis of mycolic acids (Besra and Chatterjee, 1994; Dessen et al., 1995; Wheeler and Anderson, 1996) , one of the major cell-wall components. With the widespread appearance of resistance to such drugs, new drug targets must be identified to combat mycobacterial infections. One of the unusual features of the mycobacterial cell wall is that it is composed of many unique lipids constituting 60% of the wall. An understanding of the biochemistry and molecular genetics of the cell-wall lipids would provide a rational basis for seeking drugs targeted at the production of such unique mycobacterial lipids. Recent advances in recombinant DNA technology and associated new genetics hold much promise in helping to find new solutions to the TB problem (Young and Cole, 1993) . The mycobacterial genome project is providing the nucleotide sequence that helps to identify functionally defined open reading frames (ORFs). The unusually large number of segments of mycobacterial genome that show homology to domains of polyketide synthases (pks) is consistent with the fact that mycobacteria have an unusually large number of classes of lipids. However, the enzymology and molecular genetics of biosynthesis of such mycobacterial lipids have only begun to be elucidated. We shall summarize recent advances in this area, propose the functions for some of the many polyketide synthase-type segments of the mycobacterial genome, and suggest ways to further explore the functions of others.
The wide variety of lipids in mycobacteria
Mycobacteria have an extremely wide diversity of lipids that are quite unlike the usual bacterial cellular lipids which are also present in mycobacteria (Minnikin, 1982; Brennan and Nikaido, 1995) . As the biochemistry and molecular genetics of this organism need to be understood in the context of production of such lipids, a brief look at their diversity is useful. In addition to the usual fatty acids found in membrane lipids, mycobacteria have a wide variety of very long-chain saturated (C 18 -C 32 ) and monounsaturated (up to C 26 ) n-fatty acids. The occurrence of ␣-alkyl ␤-hydroxy very long-chain fatty acids, i.e. mycolic acids, is a hallmark of mycobacteria and related species. Mycobacterial mycolic acids are the largest (C 70 -C 90 ) with the largest ␣-branch (C 20 -C 25 ). The main chain contains one or two double bonds, cyclopropane rings, epoxy groups, methoxy groups, keto groups or methyl branches. Such acids are major components of the cell wall, occurring mostly esterified in clusters of four on the terminal hexa-arabinofuranosyl units of the major cell-wall polysaccharides called arabinogalactans. They are also found esterified to the 6 and 6Ј positions of trehalose to form 'cord factor'. Small amounts of mycolate are also found esterified to glycerol or sugars such as trehalose, glucose and fructose depending on the sugars present in the culture medium. Mycobacteria also contain a wide variety of methyl-branched fatty acids. These include 10-methyl C 18 fatty acid (tuberculostearic acid found esterified in phosphatidyl inositide mannosides), 2,4-dimethyl C 14 acid and mono-, di-and trimethyl-branched C 14 to C 25 fatty acids found in trehalose-containing lipooligosaccharides, trimethyl unsaturated C 27 acid (phthienoic acid), tetramethyl-branched C 28 -C 32 fatty acids (mycocerosic acids) and shorter homologues found in phenolic glycolipids and phthiocerol esters, and multiple methyl-branched phthioceranic acids such as heptamethyl-branched C 37 acid and oxygenated multiple methyl-branched acids such as 17-hydroxy-2,4,6,8,10,12,14,16-octamethyl C 40 acid found in sulpholipids. In addition, mycocerosic acids and other branched acids are esterified to phthiocerol and phenolphthiocerol and their derivatives.
Biosynthesis of n-fatty acids
Both multifunctional fatty acid synthase (FAS) (type I), usually found in eukaryotes, and multicomponent FAS (type II), usually found in prokaryotes, have been found in mycobacteria. The multifunctional synthase catalyses not only the synthesis of C 16 and C 18 fatty acids, the normal products of de novo synthesis, but also elongation to produce C 24 and C 26 fatty acids (Wood et al., 1977; Kikuchi et al., 1992) . The bimodal distribution of products arises from the ability of the synthase to use the very short primers as is usual for de novo fatty acid synthesis, and the additional ability to use the longer primers that are the usual end-products of de novo synthesis (Kikuchi et al., 1992) . Mycobacterial O-methylated polysaccharides stimulate the rate of fatty acid synthesis by the mycobacterial FAS. The mechanism of this stimulation was suggested to be by formation of a ternary complex with the synthase and the fatty acyl-CoA product non-covalently bound to the synthase causing the release of the product to enhance the rate-limiting diffusion of the product. Since further elongation of C 16 and C 18 acids to C 24 and C 26 products results from the relative rates of condensation outcompeting with rate of release of the product, the enhancement of product release at the C 16 and C 18 level caused by the polysaccharides results not only in the increased rate of fatty acid synthesis but also in a change in product distribution in favour of C 16 and C 18 . If and how this effect of the mycobacterial carbohydrates plays a role in mycobacteria in vivo is not known. It has been suggested that FAS in M. tuberculosis in culture might function both as de novo synthase and as an elongase but when in the host it may mainly elongate the fatty acids from the host. The mycobacterial polysaccharide level might play a role in determining whether FAS would function as a de novo synthase or as an elongase.
Mycobacterial FAS is larger than the other multifunctional synthases. Presumably, this synthase has unusual acyl transferase and ketoacyl synthase domains that could account for the elongating activity of this synthase. Cloning and sequencing of the synthase gene revealed a 8389 bp ORF (Fernandes and Kolattukudy, 1996) . Comparison of the amino acid sequence with the sequence in the active-site regions of known synthases identified the domains in the cloned mycobacterial FAS gene (fas). The domain organization is like a head-to-tail fusion of the two yeast FAS subunits: acyl transferase (AT)-enoyl reductase (ER)-dehydratase (DH)-malonyl/palmitoyl transferase-acyl carrier protein (ACP) fused with ␤-ketoreductase (KR)-␤-ketoacyl synthase (KS). No additional AT or KS that could be uniquely involved in the chain elongation was found. Active-site analyses did reveal two putative active-site consensus sequences for the second nucleotide-binding KR domain. The first sequence showed 81% identity with the active-site region found in Brevibacterium ammoniagenes and the other sequence showed 40% identity to the corresponding active-site regions in mycobacterial mycocerosic acid synthase (MAS), eryA from Saccharopolyspora erythraea and rat FAS. Whether the dual site reflects the need for both NADH and NADPH for mycobacterial FAS in contrast to the single-reductant requirement of other FASs remains unknown. It is possible that there are two multifunctional FASs in mycobacteria as was recently found to be the case in Brevibacterium (Stuible et al., 1996) .
In addition to the synthase that can catalyse both de novo synthesis and fatty acid elongation, other fatty acid-elongating enzyme activities have been reported. Malonyl-CoAdependent elongating activities produce fatty acids up to C 56 (Besra and Chatterjee, 1994) . Such products are probably synthesized by multiple synthases present in the crude cell-free preparations. An ACP-independent malonyl-CoA-dependent chain-elongating activity has been resolved into 3-ketoacyl-CoA synthase, 3-ketoacyl-CoA reductase, enoyl-CoA dehydratase and enoyl-CoA reductase (Kikuchi et al., 1989) . A reconstituted elongation system composed of a combination of the purified component enzymes catalysed elongation of C 14 to C 24 saturated and mono-unsaturated primers using malonyl-CoA as the chain-extending unit and NADPH as sole reductant; the products were a mixture of n-fatty acids up to C 30 . AcylCoA elongation by a single C 2 unit using acetyl-CoA as the chain-extending moiety was also reported. The biological functions of these activities remain to be elucidated.
Biosynthesis of mycolic acids
The proposed biosynthetic pathways for the ethylenic and cyclopropanated mycolic acids are shown in Fig. 1 . This process involves fatty acid chain elongation, desaturation, cyclopropanation of the olefin and a Claisen-type condensation. Early studies on the biosynthesis of mycolic acids have been reviewed recently (Besra and Chatterjee, 1994) . More recently, mycolyl-mannosylphosphopolyprenol was identified and it was suggested that mature mycolic acids are formed from ␤-oxo precursors while attached to a mannosylphosphorylpolyprenol and then transported through the membrane for esterification to the arabinan in the wall . Although a cell-free system that incorporates [1-14 C]-acetate into mycolic acids has been described, little is known about the enzymes that catalyse individual steps postulated to be involved in mycolic acid biosynthesis. Fatty acid chain elongation and cyclopropanation have been examined. Of the four resolved component enzymes of the very long-chain fatty acid elongation system mentioned above, only the 3-oxoacyl-CoA reductase and enoyl-CoA reductase were inhibited by isoniazid, a commonly used antimycobacterial drug (Kikuchi et al., 1989) that is known to inhibit mycolic acid synthesis. The presence of isoniazid in the elongation system reconstituted from the component enzymes caused accumulation of 3-oxo fatty acid. Isoniazid was found to compete with NADPH for binding to the reductase. Consistent with these findings is the more recent conclusion that isoniazid inhibits mycolic acid synthesis by inhibiting elongation of C 24:1 (Wheeler and Anderson, 1996) . Although molecular genetic evidence suggested that enoyl reductase (InhA) is the primary target for isoniazid (Dessen et al., 1995) , more recent results indicate that InhA is not the major target for isoniazid in M. tuberculosis (Mdluli et al., 1996) .
Cyclopropanation of the two double bonds, a major modification found in the mycolic acids of pathogenic mycobacteria, may have a functional role in survival in the hostile environment within the host. To seek the genes involved in cyclopropanation, the M. tuberculosis cosmid DNA, which when introduced into M. smegmatis causes cyclopropanation of the distal cis double bond in the mycolic acid, was identified. A gene, cma1, encoding a protein that has 34% identity with the cyclopropanating enzyme of Escherichia coli, was found to be responsible for this cyclopropanation . Another gene, cma2, with 73% identity to cma1, was cloned from M. tuberculosis by homology to a putative cyclopropane synthase identified from the M. leprae sequencing project. The fact that this gene product cyclopropanates the proximal double bond was demonstrated by expression of this gene in M. smegmatis leading to cyclopropanation of the proximal olefin in the mycolic acid of M. smegmatis (George et al., 1995) . Cyclopropanation was shown to alter fluidity and permeability of the mycobacterial cell wall (Liu et al., 1996) . The methoxymycolate series found in M. tuberculosis contains a methoxy group adjacent to the methyl branch, in addition to the cyclopropane in the proximal position. Recently, the molecular genetics of this olefin modification were elucidated (Yuan and Barry, 1996) . A series of four methyl transferase genes (mm1-4 ) was cloned using the cma1 gene as a probe and their functions were deduced by analysing the structural changes in the mycolic acids caused by introduction of these methyl transferase genes. Thus, mm4 methylates the distal olefin using S-adenosyl methionine generating a carbonium ion on the adjacent carbon. It is interesting that the products of other genes in this cluster modify this methylated intermediate to generate related products. The carbonium ion reacts with a hydroxyl group and the resulting secondary alcohol is methylated by the product of the mm3 gene. Alternatively, the mm2 gene product catalyses the reaction of the methyl carbon with the carbonium ion to generate a cyclopropyl group. The function of the mm1 gene product remains to be elucidated. Thus, important progress is being made in the molecular genetics of functionally important modifications in mycolic acids.
Biosynthesis of methyl-branched fatty acids
Biosynthesis of methyl-branched fatty acids involves methylmalonyl-CoA as the chain-extending substrate instead of malonyl-CoA used for n-fatty acid biosynthesis. Vertebrate FAS preparations were shown to be capable of synthesizing multiple methyl-branched fatty acids when methylmalonyl-CoA was provided as the only chainextending substrate. These enzymes generate 2,4,6,8-tetramethyl branched acids from short (C 2 or C 3 ) primers. However, when malonyl-CoA and methylmalonyl-CoA are present, the former is highly preferred but some methylmalonyl-CoA is also used resulting in a complex mixture of products. In vertebrate tissues that specialize in the synthesis of multiple methyl-branched fatty acids, FAS produces such acids because a unique cytoplasmic malonyl-CoA decarboxylase ensures that only methylmalonylCoA would be available to the FAS in such tissues (Courchesne-Smith et al., 1992) . Alternatively, the structures of the branched acids present in mycobacteria would suggest that they are formed not by FAS but by unique enzymes specializing in the synthesis of such molecules. After a cell-free synthesis of mycocerosic acids from C 20 -CoA and methylmalonyl-CoA has been achieved, the enzyme that catalyses this unique chain elongation could be purified to homogeneity. This MAS was found to be a dimer of a multifunctional synthase, each subunit containing covalently attached phosphopantetheine (Rainwater and Kolattukudy, 1985) . The cloning and sequencing of the mycobacterial MAS gene (mas) revealed the domain organization of this enzyme in the following order: KS-AT-DH-ER-KR-ACP (Mathur and Kolattukudy, 1992) . No thioesterase domain was found in this enzyme and the mechanism of chain-termination involved in the synthesis of (C 27 -C 32 ) mycocerosic acids remains obscure (Mathur and Kolattukudy, 1992) .
Mycocerosic acids produced by the purified synthase were not released from the enzyme, suggesting that a specific enzyme might be involved in transferring the mycocerosyl group from the synthase to the two hydroxyl groups in phthiocerol and phenolphthiocerol. Such a hypothesis would be consistent with the observation that mycocerosic acids are found esterified only to these diols. An ORF (ORF3) that could encode a 64.8 kDa protein, found in close proximity to the mas gene, showed homology to enzymes that use acyl adenylates. Therefore, we speculated that the product of this ORF might be involved in the esterification of mycocerosic acids to the diols. Reverse transcription-polymerase chain reaction (RT-PCR) showed orf3 transcripts, and antibodies prepared against ORF3 protein expressed in E. coli cross-reacted with a 65 kDa protein in Mycobacterium bovis BCG cells. The 65 kDa protein isolated from this extract by immunoaffinity purification with the antibodies showed acyl-CoA synthase activity. In view of the presence of the orf3 gene in close proximity to mas, a pks and a mas-like gene in several mycobacterial species, it is tempting to suggest that the products of the orf3-like genes function selectively with the products of the neighbouring synthase genes, presumably to transfer the synthase products to their biochemical acceptors (Fitzmaurice and Kolattukudy, 1997) . Thus, for example, the ORF3 protein could either activate mycocerosic acids or function with a membrane-localized protein to transfer mycocerosyl groups from the synthase to the diols. Consistent with such a hypothesis is our observation that immunogold labelling showed that MAS is associated with the outer membrane/cell-wall complex, whereas a similar method showed that FAS is in the cytoplasm in M. bovis BCG (L. B. Bakaletz and P. E. Kolattukudy, unpublished). We have found another ORF (ORF2) in close proximity to mas; this ORF is, in fact, expressed and the product was found to be located in the membrane (A. M. Fitzmaurice and P. E. Kolattukudy, unpublished) . Whether this protein and ORF3 product together can function in mycocerosyl transfer is not known.
The purified MAS shows a preference for elongation by four methylmalonyl-CoA units, reflecting the natural composition of mycocerosic acids. Therefore, it would seem probable that each class of methyl-branched fatty acids is synthesized by a separate enzyme. The fatty acids esterified to phenolphthiocerol are mainly mycocerosic acids but shorter methyl-branched fatty acids are also esterified to phthiocerol. This class of branched acids are synthesized by an enzyme that has been recently resolved from MAS (N. D. Fernandes and P. E. Kolattukudy, unpublished) . The diversity of branched fatty acids found in mycobacteria would require many different synthases. Little is known about the enzymes involved in the synthesis of the other classes of methyl-branched acids.
The enzyme domains that determine whether malonylCoA or methylmalonyl-CoA is selected for the synthesis of polyketide-type natural products are not known. The AT and KS domains of MAS showed a much higher degree of homology to the corresponding domains of the polyketide synthase involved in the synthesis of multiple methyl-branched aglycone of erythromycin than to the corresponding domains of vertebrate FAS that synthesizes n-fatty acids (Mathur and Kolattukudy, 1992) . Therefore, we postulated that the substrate specificity of the AT and KS domains is responsible for selectively using malonyl-CoA or methylmalonyl-CoA. This hypothesis was tested with the AT and KS domains of MAS expressed in E. coli. The expressed domains enabled FAS preparations from E. coli and M. smegmatis to incorporate methylmalonylCoA into fatty acids (N. D. Fernandes and P. E. Kolattukudy, in preparation) . This incorporation required a primer and ACP. Thus, specificity for methylmalonyl-CoA probably resides in the AT and KS domains of MAS.
Biosynthesis of phthiocerol and phenolphthiocerol
Based on current biochemical concepts, the most probable biochemical pathways for phthiocerol and phenolphthiocerol can be postulated as shown in Fig. 2 . Biosynthesis of phthiocerol and phenolphthiocerol would involve elongation of preformed n-C 20 fatty acyl chains or an acyl chain containing a phenol residue at the -end. The synthesis of the p-hydroxyphenylalkanoic acid precursor could be catalysed by FAS (or an analogous enzyme) from p-hydroxybenzoyl-CoA as the starter with malonyl-CoA as the elongating substrate. FASs are known to have seldom-used but inherent capabilities to use starters other than acetyl-CoA and substrates other than malonyl-CoA to generate unusual fatty acids (Courchesne-Smith et al., 1992) , and benzoyl-CoA appears to be elongated to very long-chain fatty acids by M. bovis BCG extracts (N. D. Fernandes and P. E. Kolattukudy, unpublished) .
Synthesis of phthiocerol and phenolphthiocerol from the appropriate precursor would involve elongation first with malonyl-CoA and then by two methylmalonyl-CoA units, followed by decarboxylation and reduction. As in the case of erythronolide synthesis, during some elongation cycles, the dehydration and reduction steps are missed; after the last elongation with methylmalonyl-CoA, before the carbonyl group is reduced, decarboxylation probably occurs. The ␤-keto group would assist the decarboxylation reaction by serving as a transient electron sink. The natural occurrence of the keto derivative is consistent with this postulate. Overall, the biosynthetic strategy for this unique mycobacterial aglycone could be analogous to that used for erythronolide biosynthesis (Katz and Donadio, 1993) . Thus, the synthesis of phthiocerols probably involves multifunctional proteins with similarity to eryA gene products, FAS, and MAS. It is probable that one FAS-like protein, which lacks DH and ER domains, would catalyse the first two cycles to generate the dihydroxy intermediate (Compound I, Fig. 2) , which would then be elongated with two units of malonyl-CoA by a FAS-like enzyme containing all of the normal domains yielding the next intermediate (Compound II, Fig. 2 ). Another multifunctional protein with selectivity for methylmalonyl-CoA, as in MAS, could then catalyse the subsequent elongation with methylmalonyl-CoA followed by condensation with a final methylmalonyl-CoA unit to generate the ␤-keto derivative (Compound III, Fig. 2) . The domain organization of the enzymes required to catalyse these reactions is shown in Fig. 2 .
The postulated enzymological strategy is remarkably analogous to that used in macrocyclic lactone synthesis by another group of organisms within the actinomycetes (Katz and Donadio, 1993) and the process would require several multifunctional proteins functioning in conjunction with each other. This situation could make it difficult to obtain cell-free systems that effectively catalyse the synthesis of phenolphthiocerol, as in the case of erythromycin biosynthesis where the search for cell-free synthesis failed for decades and only the recent genetic approach could elucidate the complex nature of the enzymes that must be involved in erythronolide synthesis (Cortes et al., 1990; Donadio et al., 1991) . Thus, it might be possible to more easily approach the biosynthesis of phthiocerol and phenolphthiocerol by using genetic manipulations.
The phenolphthiocerol synthase gene (pps) should contain active-site motifs of the AT and KS domains of the mas gene for synthesis of methyl-branched segments and AT and KS domains of fas for the synthesis of the straight-chain segments. Therefore, a search was made for the pps gene by screening an M. bovis BCG cosmid library in pYUB18 at low stringency with probes containing the active-site motifs of the AT and KS domains of mas, and the positive clones were screened with probes for the active-site motifs of fas (A. K. Azad, T. D. Sirakova and P. E. Kolattukudy, unpublished) . Cosmid DNA isolated from the clones that were positive for both mas and fas probes was subjected to Southern hybridization analysis using AT, KS, KR, ER and ACP domain probes of mas and AT and KS domain probes of fas. DNA sequence analysis of these cosmids and their restriction patterns showed the relative positions of the pks-like genes and mas in the mycobacterial genome (Fig. 3) . M. leprae L518 cosmid contains six pks-like ORFs and a corresponding segment of the M. tuberculosis genome (cosmids MTCY338 and MTCY19H9) contains five ORFs with domain organization that matches the theoretical domain organization proposed for pps genes (pps1, pps2, pps3, pps4 and pps5; Fig. 2 
Disruption of genes involved in the cell-wall lipid biosynthesis
The large number of enzymes involved in the biosynthesis of the great diversity of lipids present in mycobacteria requires a large number of pks-like genes. Therefore, it is not surprising that the genomic sequence of mycobacteria reveal many such genes. Elucidation of the function of such genes will require multiple approaches, including classical biochemical approaches such as that used for mycocerosic acid synthesis, as well as molecular genetic approaches including cloning of the genes, targeted gene disruption and testing of biochemical and physiological consequences. Recently, the mas gene was disrupted in M. bovis BCG using a construct in which an internal 2 kb segment in the mas gene was replaced with a hygromycin-resistance gene (hyg) of approximately the same size such that hyg was flanked by 4.7 and 1.4 kb segments of mas (Azad et al., 1996) . The gene-disrupted mutant was not able to synthesize mycoside B. Obviously, mycocerosic acids that constitute the major acyl moieties in mycoside B cannot be substituted and, thus, mycoside could not be produced by the mutant in the absence of mycocerosic acids. On the other hand, the acyl portion of the wax-type esters is composed of methyl-branched acids shorter than mycocerosic acids and some mycocerosic acids. The mas-disrupted mutant produced phthiocerol esters which contained only the shorter methylbranched acids. Obviously, these branched acids are produced by enzymes other than MAS. In fact, a protein fraction that catalysed the synthesis of these specific branched acids was obtained from the extracts of a masdisrupted mutant (N. D. Fernandes and P. E. Kolattukudy, unpublished) , thus clearly distinguishing two enzymes involved in branched fatty acid synthesis.
Disruption of the mas gene also revealed the presence of a MAS-like protein of the same size as MAS, and proteolytic fragments showed a high degree of amino acid sequence identity with the corresponding segments of MAS. This MAS-like protein cross-reacted with MAS antibodies. The catalytic function of this protein is not known. The gene that encodes this protein was cloned and sequenced and it was found to be highly homologous to mas (T. D. Sirakova, A. K. Azad and P. E. Kolattukudy, unpublished) .
Although the biochemical consequences of mas disruption were clear, the functional consequences are not yet known. There are indications of alterations in the cell wall, enhanced uptake of lipophilic materials, and increased susceptibility to drugs and host defences. Whether the lack of soluble lipids such as mycosides would enhance protein secretion, as recently observed with mycolic acid synthesis inhibition (Bardou et al., 1996) , is not known.
Conclusion
Biochemistry and molecular genetics of the complex unique lipids that constitute a major component of the mycobacterial cell wall present a real challenge because of the technical difficulties caused by the unusual structures of the molecules and the slow-growth characteristics of the organism. However, the diversity of structures present in this organism makes it a fascinating system to elucidate the complex biochemical pathways and to seek interesting enzymes and the unique genes that encode them. The uniqueness of the mycobacterial cell-wall lipids makes the biosynthesis of such lipids appropriate targets for new antimycobacterial drugs that are desperately needed to meet a major health-care need. The recent advances in mycobacterial molecular genetics are beginning to help determine the consequences of disrupting genes involved in the synthesis of specific components of the cell wall. The other approach is to test the consequences of the modification of cell-wall lipids in fast-growing organisms resulting from the expression of genes involved in the synthesis of unique components in the slow-growing pathogenic mycobacteria. Both approaches will begin to reveal the biochemical function of such genes and the physiological roles of their products, leading to identification of appropriate targets for new antimycobacterial drugs.
